|
|
To translate research findings into clinical practice,
the Canadian Partnership Against Cancer is collaborating with
the Terry Fox Research Institute on the Pan-Canadian Cancer Biomarker
Initiative. The work’s focus is practical: to identify emerging
technologies that can improve early detection and treatment methods
using biomarkers, which are biochemical features that indicate
the progress of disease or the effects of therapy.
The initiative focuses on five types of cancer — breast, leukemia and lymphoma, lung, ovarian and prostate.
The most prominent undertaking so far is the Early Lung Cancer Detection Study.
This study explores the use of questionnaires, a spirometry breathing test and a blood biomarker test
to evaluate the effectiveness of identifying individuals at high risk of developing lung cancer.
The aim is to identify Canadians who might benefit from more in-depth examination using spiral computed
tomography (CT) scanning — a more sensitive, costlier test being studied internationally to determine
its effectiveness in reducing mortality.
For more information,
|
|
|
